The FDA has given clearance to the Dexcom G7 continuous glucose monitoring system for use in type 1 and 2 diabetes in all patients aged 2 years and older.
The product is expected to launch in the United States in early 2023 and Dexcom will offer accessible cash payment options to ensure patients can transition to the new system as insurance coverage switches over.
In addition to features already included with Dexcom G6 - such as no fingersticks, glucose readings sent every 5 minutes, and predictive low alert - users will get a host of new features that includes:
30-minute sensor warmup, which is the fastest available.
Simplified mobile app.
Improved alert settings.
Less waste because of smaller plastic components.
A 12-hour grace period to replace finished sensors.
The company is also working with insulin pump partners to ensure that automated insulin delivery systems can be used with the G7 as soon as possible.
In a release from Dexcom, both diabetes patients and health care providers noted that the clearance would lead to improved care for patients.
Join the HealthXL Masterclass on the ‘DTx Access Negotiation and Contracting with Commercial Health Plans in the US’ on 15th December. Click here to Request to Join.
Click here to read the original news article.